Cargando…

Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis

OBJECTIVE: To evaluate correlations between variability in central foveal thickness (CFT) and vision with ranibizumab in a HARBOR post hoc analysis. METHODS AND ANALYSIS: Patients with neovascular age-related macular degeneration (nAMD; N=1097) received monthly or as-needed (PRN) ranibizumab (0.5 or...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheth, Veeral, D'Rozario, Mitchell, Gune, Shamika, Blotner, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915331/
https://www.ncbi.nlm.nih.gov/pubmed/35342822
http://dx.doi.org/10.1136/bmjophth-2021-000957
_version_ 1784667996089745408
author Sheth, Veeral
D'Rozario, Mitchell
Gune, Shamika
Blotner, Steven
author_facet Sheth, Veeral
D'Rozario, Mitchell
Gune, Shamika
Blotner, Steven
author_sort Sheth, Veeral
collection PubMed
description OBJECTIVE: To evaluate correlations between variability in central foveal thickness (CFT) and vision with ranibizumab in a HARBOR post hoc analysis. METHODS AND ANALYSIS: Patients with neovascular age-related macular degeneration (nAMD; N=1097) received monthly or as-needed (PRN) ranibizumab (0.5 or 2.0 mg) for 24 months. Fluctuation scores were used to assess CFT variability; every time CFT increased and then decreased (or vice versa), numeric value of the change was added to the score. Magnitude of change <50 µm was considered clinically insignificant and did not count towards the score. Fluctuation scores were grouped into quartiles. Least squares mean (LSM) changes in best-corrected visual acuity (BCVA) were plotted against fluctuation score quartiles for CFT, subretinal fluid (SRF) height, neurosensory retina and neurosensory retina + subretinal hyper-reflective material. RESULTS: Patients with lower fluctuations scores (quartiles 1–3) had greatest vision gains at month 24, with LSM changes from baseline of 9.0–10.8 and 8.7–10.6 letters in the monthly and PRN arms, respectively. Corresponding changes for quartile 4 were 6.7 and 6.5 letters, respectively. There were no differences between quartiles for association between fluctuations in SRF height and BCVA gains. There were inverse correlations between magnitude of fluctuations in neurosensory and inner retina thickness and BCVA gains for quartile 4 vs quartiles 1–3. Patients in quartiles 1 and 2 showed rapid, robust BCVA gains, whereas those in quartiles 3 and 4 had lesser responses. CONCLUSIONS: Fluctuations in retinal thickening with ranibizumab may be associated with treatment response in patients with nAMD. TRIAL REGISTRATION NUMBER: NCT00891735.
format Online
Article
Text
id pubmed-8915331
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89153312022-03-25 Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis Sheth, Veeral D'Rozario, Mitchell Gune, Shamika Blotner, Steven BMJ Open Ophthalmol Original Research OBJECTIVE: To evaluate correlations between variability in central foveal thickness (CFT) and vision with ranibizumab in a HARBOR post hoc analysis. METHODS AND ANALYSIS: Patients with neovascular age-related macular degeneration (nAMD; N=1097) received monthly or as-needed (PRN) ranibizumab (0.5 or 2.0 mg) for 24 months. Fluctuation scores were used to assess CFT variability; every time CFT increased and then decreased (or vice versa), numeric value of the change was added to the score. Magnitude of change <50 µm was considered clinically insignificant and did not count towards the score. Fluctuation scores were grouped into quartiles. Least squares mean (LSM) changes in best-corrected visual acuity (BCVA) were plotted against fluctuation score quartiles for CFT, subretinal fluid (SRF) height, neurosensory retina and neurosensory retina + subretinal hyper-reflective material. RESULTS: Patients with lower fluctuations scores (quartiles 1–3) had greatest vision gains at month 24, with LSM changes from baseline of 9.0–10.8 and 8.7–10.6 letters in the monthly and PRN arms, respectively. Corresponding changes for quartile 4 were 6.7 and 6.5 letters, respectively. There were no differences between quartiles for association between fluctuations in SRF height and BCVA gains. There were inverse correlations between magnitude of fluctuations in neurosensory and inner retina thickness and BCVA gains for quartile 4 vs quartiles 1–3. Patients in quartiles 1 and 2 showed rapid, robust BCVA gains, whereas those in quartiles 3 and 4 had lesser responses. CONCLUSIONS: Fluctuations in retinal thickening with ranibizumab may be associated with treatment response in patients with nAMD. TRIAL REGISTRATION NUMBER: NCT00891735. BMJ Publishing Group 2022-03-09 /pmc/articles/PMC8915331/ /pubmed/35342822 http://dx.doi.org/10.1136/bmjophth-2021-000957 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Sheth, Veeral
D'Rozario, Mitchell
Gune, Shamika
Blotner, Steven
Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis
title Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis
title_full Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis
title_fullStr Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis
title_full_unstemmed Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis
title_short Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis
title_sort fluctuations in central foveal thickness and association with vision outcomes with anti-vegf therapy for namd: harbor post hoc analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915331/
https://www.ncbi.nlm.nih.gov/pubmed/35342822
http://dx.doi.org/10.1136/bmjophth-2021-000957
work_keys_str_mv AT shethveeral fluctuationsincentralfovealthicknessandassociationwithvisionoutcomeswithantivegftherapyfornamdharborposthocanalysis
AT drozariomitchell fluctuationsincentralfovealthicknessandassociationwithvisionoutcomeswithantivegftherapyfornamdharborposthocanalysis
AT guneshamika fluctuationsincentralfovealthicknessandassociationwithvisionoutcomeswithantivegftherapyfornamdharborposthocanalysis
AT blotnersteven fluctuationsincentralfovealthicknessandassociationwithvisionoutcomeswithantivegftherapyfornamdharborposthocanalysis